Propanc Health Group Corp (OTCMKTS:PPCH) a growing healthcare entity focusing on the formulation of proprietary treatments for cancer patients released the first set of data from its series of animal trials, with PRP showing no unfavorable clinical symptoms at the maximum tolerated dose in mice when treated by I.V injection. The dose that is more than twice of the human equivalent dose given to patients for compassionate use is here referred to as the Maximum Tolerated Dose.

The expert view

Propanc’s Chief Scientific Officer, Dr Julian Kenyon said that the results are significant as it gives the team confident on safety and tolerability of PRP when given by I.V injection at higher doses. Furthermore, the company can now presume 100% of the medication has been absorbed into the patient’s bloodstream. It was not the case when the team first administered enrollments with proenzymes with a suppository formulation, which is anticipated to reflect a lower absorption rate.

Before the MTD mice trial, the proenzymes were individually evaluated to estimate activity in cell culture trials, with both active ingredients showing inhibitory movements in ovarian and pancreatic cancer cell lines.

The information

Professor Klaus Kutz, who is Chief Medical Officer of Propanc, said that these trials are structured to obtain valuable data about PRP when given by I.V Injection. The team is generating vital information for the numerous regulatory agencies and potential licensing partners. It helps the company to achieve a solid data package and a strong base to support the advancement of PRP into human trials.

Propanc Health Group Corp (OTCMKTS:PPCH) is an emerging healthcare firm and have team of scientific and oncology consultants. The team is working on the development of a composite and rational formulation of anti-cancer compounds. In last trading session, the stock price of Propanc jumped more than 51% to close the trading session at $0.0578. The gains came at a massive share volume of 25.79 million.